Elbion AG reeled in €25 million in Germany’s first significant biotech financing of 2005. The company, which was formed through a management buyout of some of Degussa AG’s pharmaceutical assets in 2002, concentrates on the discovery and development of small molecules that are effective against inflammatory and central nervous system diseases.
